AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26377415 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mm and 4 mm optical zone lenses
Number of subjects: 30
Study 26377415 — intervention group
Group type: EXPERIMENTAL
Intervention: All optical zone diameters
Number of subjects: 30
Study 26377415 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced pigment-free optical zone diameters
Number of subjects: 30
Study 26377597 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin monotherapy
Number of subjects: 27
Study 26377635 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery (60 patients); 78% abdominal fundoplication, 10% Belsey Mark IV, 8% laparotomic Collis-Nissen fundoplication, 3% Pearson operation
Number of subjects: 108
Study 26377635 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (48 patients); 44% laparoscopic floppy Nissen, 56% left thoracoscopic Collis-laparoscopic Nissen
Number of subjects: 108
Study 26379127 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheostomy
Number of subjects: 86
Study 26379163 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) as oral solution or capsule sprinkle plus didanosine and emtricitabine (FTC)
Number of subjects: 37
Study 26379163 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) as capsule sprinkle
Number of subjects: 37
Study 26379163 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 37
Study 26379282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 5 mg/m2 romidepsin once weekly for 3 weeks while maintaining ART
Number of subjects: 6
Study 26379437 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphocholine (PC) PC(O-12:0/2:0)
Number of subjects: 26
Study 26379437 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphocholine (PC) PC(O-14:1/2:0)
Number of subjects: 26
Study 26379437 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphocholine (PC) PC(O-17:3/2:0)
Number of subjects: 26
Study 26379437 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphocholine (PC) PC(O-18:3/2:0)
Number of subjects: 26
Study 26379759 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (150 ± 106 mg/day)
Number of subjects: 26
Study 26379759 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 26
Study 26380086 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab (10 mg/kg IV every 3 weeks, 2 doses)
Number of subjects: 35
Study 26380086 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-17 level
Number of subjects: 35
Study 26380086 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline TGF-β1 and IL-10 levels
Number of subjects: 35
Study 26380086 — intervention group
Group type: EXPERIMENTAL
Intervention: Week 6 cytokines
Number of subjects: 35
Study 26380150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib with concomitant ESA administration
Number of subjects: 146
Study 26380150 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 146
Study 26380731 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin calcium BID (4,100 AxaIU q12h)
Number of subjects: 111
Study 26380731 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin calcium QD (4,100 AxaIU qd + placebo qd)
Number of subjects: 111
Study 26380993 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 24
Study 26381120 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning services (FP)
Number of subjects: 1887
Study 26381120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual use of FP
Number of subjects: 1887
Study 26381120 — intervention group
Group type: EXPERIMENTAL
Intervention: Unintended pregnancies
Number of subjects: 1887
Study 26381120 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting contraceptives
Number of subjects: 1887
Study 26381530 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (3mg/m²/day, titrated to target blood trough levels of 5-15ng/ml)
Number of subjects: 28
Study 26381736 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg) administered 0.5 hours before cangrelor discontinuation
Number of subjects: 0
Study 26381736 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg) administered 1 hour before cangrelor discontinuation
Number of subjects: 0
Study 26381736 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel administered immediately after cangrelor discontinuation
Number of subjects: 0
Study 26382006 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI data acquisition during passive fixation with visual stimuli presented at various locations
Number of subjects: 0
Study 26382006 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral and ipsilateral stimulus pairs with different textures and shapes
Number of subjects: 0
Study 26382051 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-based confocal laser endomicroscopy (nCLE) during EUS
Number of subjects: 15
Study 26382051 — intervention group
Group type: EXPERIMENTAL
Intervention: Final diagnosis
Number of subjects: 15
Study 26382589 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 26382589 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNF agents
Number of subjects: 0
Study 26382589 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 26383952 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary infection antisera
Number of subjects: 0
Study 26384013 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 2772
Study 26384102 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic feature analysis
Number of subjects: 5
Study 26384102 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated attempts to name untreated items
Number of subjects: 5
Study 26384102 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of the names of untrained items
Number of subjects: 5
Study 26384164 — intervention group
Group type: EXPERIMENTAL
Intervention: Human CD133(+) bone marrow-derived stem cells (BMDSCs) injected intrauterinely
Number of subjects: 10
Study 26384164 — intervention group
Group type: EXPERIMENTAL
Intervention: Human CD133(+) bone marrow-derived stem cells (BMDSCs) injected systemically through the tail vein
Number of subjects: 10
Study 26384163 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH levels throughout the menstrual cycle
Number of subjects: 40
Study 26384163 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean AMH concentrations
Number of subjects: 40
Study 26384163 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean luteal AMH levels
Number of subjects: 40
Study 26384163 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of antral follicles estimated from AMH levels
Number of subjects: 40
Study 26384163 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH concentrations
Number of subjects: 40
Study 26384163 — intervention group
Group type: EXPERIMENTAL
Intervention: Preovulatory AMH levels
Number of subjects: 40
Study 26384204 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 0
Study 26384204 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation TAVI devices
Number of subjects: 0
Study 26384204 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI registries data
Number of subjects: 0
Study 26384354 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, pomalidomide, and dexamethasone (CPD)
Number of subjects: 32
Study 26384469 — intervention group
Group type: EXPERIMENTAL
Intervention: Status epilepticus with good outcome
Number of subjects: 47
Study 26384469 — intervention group
Group type: COMPARATOR
Intervention: Status epilepticus with poor outcome
Number of subjects: 47
Study 26384573 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese parent version of the Autism Spectrum Rating Scale (ASRS)
Number of subjects: 1836
Study 26384710 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality indicators for perioperative diabetes care
Number of subjects: 389
Study 26384789 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus vinorelbine (lap+vin)
Number of subjects: 112
Study 26384789 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib plus capecitabine (lap+cap)
Number of subjects: 112
Study 26385385 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemosensitivity test (CD-DST) using four different concentrations of 5-fluorouracil
Number of subjects: 206
Study 26385385 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with S-1
Number of subjects: 206
Study 26385402 — intervention group
Group type: EXPERIMENTAL
Intervention: Midfollicular serum SHBG concentrations
Number of subjects: 319
Study 26385462 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor antagonist exendin 9-39 (during infusion)
Number of subjects: 40
Study 26385462 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) infusion
Number of subjects: 40
Study 26386044 — intervention group
Group type: EXPERIMENTAL
Intervention: Biallelic mutations in KIAA0586
Number of subjects: 6
Study 26386044 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblasts from patients with Jeune-Joubert syndrome
Number of subjects: 6
Study 26386044 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue with full-length wild type KIAA0586
Number of subjects: 6
Study 26386044 — intervention group
Group type: EXPERIMENTAL
Intervention: KIAA0586 RNA expression levels
Number of subjects: 6
Study 26386667 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4030
Study 26386794 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet function testing
Number of subjects: 10048
Study 26386794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic testing
Number of subjects: 10048
Study 26386794 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-potency adenosine diphosphate receptor inhibitors (prasugrel/ticagrelor)
Number of subjects: 10048
Study 26387127 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 0
Study 26387127 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 0
Study 26387811 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 214
Study 26387810 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF (hemodiafiltration)
Number of subjects: 36
Study 26387810 — intervention group
Group type: COMPARATOR
Intervention: BHD (bicarbonate dialysis)
Number of subjects: 36
Study 26388950 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality enhancement programmes in public primary care
Number of subjects: 127977
Study 26389799 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzimidazoles treatment (abrogated after normalization of FDG-PET/CT and anti-EmII/3-10 levels)
Number of subjects: 34
Study 26389799 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B with continued chemotherapy)
Number of subjects: 34
Study 26389849 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of veltuzumab (80, 160, or 320 mg every 2 weeks × 4 doses)
Number of subjects: 21
Study 26389849 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of veltuzumab (160 or 320 mg twice-weekly × 16 doses)
Number of subjects: 21
Study 26389849 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of veltuzumab
Number of subjects: 21
Study 26390038 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu5F9-G4 (humanized anti-CD47 antibody)
Number of subjects: 0
Study 26390038 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu5F9-G4 (humanized anti-CD47 antibody) + rituximab
Number of subjects: 0
Study 26390837 — intervention group
Group type: EXPERIMENTAL
Intervention: COVA322 (bispecific TNF/IL-17A inhibitor)
Number of subjects: 0
Study 26391016 — intervention group
Group type: EXPERIMENTAL
Intervention: LVIS device
Number of subjects: 31
Study 26391354 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with at least one sensitive TAS2R38 allele (AP or PP genotype)
Number of subjects: 172
Study 26391354 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's reports of past problems with medication
Number of subjects: 172
Study 26391458 — intervention group
Group type: EXPERIMENTAL
Intervention: Zenith Alpha thoracic endovascular graft
Number of subjects: 50
Study 26391648 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with RCTs
Number of subjects: 20
Study 26391665 — intervention group
Group type: EXPERIMENTAL
Intervention: AV300 vein viewer
Number of subjects: 238
Study 26391665 — intervention group
Group type: COMPARATOR
Intervention: Standard peripheral IV cannulation without supporting device (control group)
Number of subjects: 238
Study 26392035 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency, low-magnitude vibration signal (approximately 33Hz and 0.3g)
Number of subjects: 28
Study 26392057 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood pneumonia
Number of subjects: 10192
Study 26392057 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood pneumonia with asthma
Number of subjects: 10192
Study 26392102 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg twice daily) plus Trametinib (2 mg daily)
Number of subjects: 43
Study 26392102 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus Trametinib
Number of subjects: 43
Study 26392348 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a therapy for nine days
Number of subjects: 50
Study 26392763 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical activity level (PAL) measured by activity monitor (SenseWear Pro™)
Number of subjects: 123
Study 26392763 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PAL
Number of subjects: 123
Study 26392838 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 0
Study 26392838 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26393854 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation with Androgen Deprivation Therapy
Number of subjects: 0
Study 26393854 — intervention group
Group type: COMPARATOR
Intervention: Radiation without Androgen Deprivation Therapy
Number of subjects: 0
Study 26394198 — intervention group
Group type: EXPERIMENTAL
Intervention: A2NTX (low-molecular weight subtype A2 preparation)
Number of subjects: 0
Study 26394198 — intervention group
Group type: COMPARATOR
Intervention: onabotulinumtoxinA (A1LL)
Number of subjects: 0
Study 26394202 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (8 mg/kg) administered 1 hour after injury and every 12 hours thereafter for 7 days at 6 mg/kg
Number of subjects: 3
Study 26394202 — intervention group
Group type: COMPARATOR
Intervention: Vehicle solution (control group)
Number of subjects: 3
Study 26394202 — intervention group
Group type: COMPARATOR
Intervention: Sham injured rats (C2 laminectomy without hemisection)
Number of subjects: 3
Study 26394823 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with MLBW at 3.5 years
Number of subjects: 285
Study 26394823 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with MLBW at 7 years
Number of subjects: 285
Study 26394823 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with MLBW
Number of subjects: 285
Study 26394823 — intervention group
Group type: COMPARATOR
Intervention: Control children
Number of subjects: 285
Study 26395347 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib (300 mg once every 3 weeks) + Nintedanib (200 mg twice daily)
Number of subjects: 30
Study 26395347 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib + Nintedanib
Number of subjects: 30
Study 26395501 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CCP positive individuals
Number of subjects: 2028
Study 26395501 — intervention group
Group type: COMPARATOR
Intervention: Anti-CCP negative individuals
Number of subjects: 2028
Study 26396053 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosed intravenous methylprednisolone therapy
Number of subjects: 0
Study 26396053 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune prophylaxis with beta-interferon or glatiramer acetate
Number of subjects: 0
Study 26396157 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (300 mg twice a day) plus raltegravir (400 mg twice a day)
Number of subjects: 44
Study 26396720 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones capsules
Number of subjects: 67
Study 26396720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 26398152 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD)
Number of subjects: 1825
Study 26398152 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis (OP)
Number of subjects: 1825
Study 26398152 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1825
Study 26398290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting triglycerides
Number of subjects: 158
Study 26398290 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-challenge triglycerides
Number of subjects: 158
Study 26398290 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fat challenge
Number of subjects: 158
Study 26398503 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir plus pegylated interferon-α and ribavirin (PR) for 12 weeks followed by PR alone.
Number of subjects: 1772
Study 26398503 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline FibroScan values.
Number of subjects: 1772
Study 26398503 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher FibroScan values.
Number of subjects: 1772
Study 26400226 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermistor-based tympanic temperature (T tymp) measurement after exposure to cooling conditions.
Number of subjects: 13
Study 26400226 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermistor-based tympanic temperature (T tymp) measurement after 10 min of cooling exposure.
Number of subjects: 13
Study 26400297 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCs/HGF (autologous bone marrow MSCs transfected with human HGF cDNA) administered intravenously at a dose of 2 x 10(6) cells/kg, weekly for three consecutive weeks.
Number of subjects: 4
Study 26400297 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCs/HGF
Number of subjects: 4
Study 26400368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 1061
Study 26400368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study 26400417 — intervention group
Group type: EXPERIMENTAL
Intervention: HVSP (volitional hyperventilation at spontaneous breathing rate)
Number of subjects: 18
Study 26400417 — intervention group
Group type: EXPERIMENTAL
Intervention: HV20 (volitional hyperventilation at 20/min)
Number of subjects: 18
Study 26400417 — intervention group
Group type: EXPERIMENTAL
Intervention: SP1 (spontaneous breathing protocol 1)
Number of subjects: 18
Study 26400417 — intervention group
Group type: EXPERIMENTAL
Intervention: SP2 (spontaneous breathing protocol 2)
Number of subjects: 18
Study 26401247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron therapy
Number of subjects: 15
Study 26401256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 11
Study 26402159 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy for 3 weeks
Number of subjects: 58
Study 26402159 — intervention group
Group type: COMPARATOR
Intervention: Aging
Number of subjects: 58
Study 26402736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance therapy with a custom-made, titratrable mandibular advancement device (OAm)
Number of subjects: 51
Study 26403509 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2090314 (40 mg) plus pemetrexed (500 mg/m2) and carboplatin (5-6 AUC) every 21 days
Number of subjects: 41
Study 26403509 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2090314 monotherapy (≥ 40 mg)
Number of subjects: 41
Study 26403509 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2090314 (40 mg) plus pemetrexed/carboplatin
Number of subjects: 41
Study 26403509 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2090314 (40 mg)
Number of subjects: 41
Study 26404501 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported fatigue severity
Number of subjects: 280
Study 26404501 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk IPSS score
Number of subjects: 280
Study 26404501 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue assessment in multivariate models
Number of subjects: 280
Study 26404729 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified uvulopalatopharyngoplasty (UPPP) surgery
Number of subjects: 65
Study 26404729 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 65
Study 26405287 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe asthma
Number of subjects: 282
Study 26405287 — intervention group
Group type: COMPARATOR
Intervention: Mild/moderate asthma
Number of subjects: 282
Study 26405521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac output monitoring
Number of subjects: 12170
Study 26405521 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous catheter
Number of subjects: 12170
Study 26405521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac output monitoring in elective surgery
Number of subjects: 12170
Study 26405521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac output monitoring in urgent surgery
Number of subjects: 12170
Study 26405521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac output monitoring in emergency surgery
Number of subjects: 12170
Study 26405521 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous catheter in elective surgery
Number of subjects: 12170
Study 26405521 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous catheter in urgent surgery
Number of subjects: 12170
Study 26405521 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous catheter in emergency surgery
Number of subjects: 12170
Study 26405521 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial waveform analysis
Number of subjects: 12170
Study 26405521 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal Doppler ultrasound
Number of subjects: 12170
Study 26405521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter
Number of subjects: 12170